ANIMAL EXPERIMENT;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
BIOLOGICAL ACTIVITY;
CANCER INHIBITION;
COLON ADENOCARCINOMA;
DRUG BIOAVAILABILITY;
DRUG HALF LIFE;
DRUG SCREENING;
DRUG STABILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
FEMALE;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO CULTURE;
INTESTINE FLUID;
LIVER CELL CARCINOMA;
MAXIMUM PLASMA CONCENTRATION;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
TIME TO MAXIMUM PLASMA CONCENTRATION;
The role of deoxycytidine kinase in gemcitabine cytotoxicity
van der Wilt C.L., Kroep J.R., Bergman A.M., Loves W.J., Alvarez E., Talianidis I., Eriksson S., van Groeningen C.J., Pinedo H.M., Peters G.J. (2000) The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol;486:287-290.
Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation
Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. (1992) Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res;52:533-539.
2′, 2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines
Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. (1993) 2′, 2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol;46:762-766.
Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs
Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., Culp H.W. (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos;20:849-855.
Specific features of toxicological profile of gemcitabine, an antitumor agent from the group of anti-metabolites
Parshina N.A., Baǐkova V.N., Pleteneva T.V. (2010) Specific features of toxicological profile of gemcitabine, an antitumor agent from the group of anti-metabolites. Sud Med Ekspert;53:39-42.
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine
Bender D.M., Bao J., Dantzig A.H., Diseroad W.D., Law K.L., Magnus N.A., Peterson J.A. et al. (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem;52:6958-6961.
Membrane affinity and metabolism of N4-palmitoyl-1-beta-d-arabinofuranosylcytosine into cultured KB cells
Tsuruo T., Iida H., Hori K., Tsukagoshi S., Sakurai Y. (1981) Membrane affinity and metabolism of N4-palmitoyl-1-beta-d-arabinofuranosylcytosine into cultured KB cells. Cancer Res;41:4484-4488.
Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine - synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid
Nielsen A.B., Buur A., Larsen C. (2005) Bioreversible quaternary N-acyloxymethyl derivatives of the tertiary amines bupivacaine and lidocaine - synthesis, aqueous solubility and stability in buffer, human plasma and simulated intestinal fluid. Eur J Pharm Sci;24:433-440.
Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II
Xue X., Qu X.J., Gao Z.H., Sun C.C., Liu H.P., Zhao C.R., Cheng Y.N., Lou H.X. (2012) Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest New Drugs;30:212-222.
LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin
Gao J.J., Gao Z.H., Zhao C.R., Yuan Y., Cui S.X., Zhang X.F., Cheng Y.N., Xu W.F., Tang W., Qu X.J. (2011) LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin. Invest New Drugs;29:574-582.
Ligand creation via linking-a rapid and convenient method for construction of novel supported PyOX-ligands
Oila M.J., Tois J.E., Koskinen A.M.P. (2005) Ligand creation via linking-a rapid and convenient method for construction of novel supported PyOX-ligands. Tetrahedron;61:10748-10756.
